ScreenerHero

PBLA Panbela Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · panbela.com
0.0111USD+11000.00%Mkt Cap: 53888 $P/E: —

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product cand…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap53.89K USD
Enterprise Value1.67M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-25.26M USD
Revenue/Share—
Last Price0.0111 USD
Fiscal Year EndDec 2023
MR QuarterSep 2024
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS69833W2061
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.00
EPS (TTM)-1915.86
EPS (Forward)-5.66
52W Range
0.00010% of range2.500
52W High2.500 USD
52W Low0.0001 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE536.37%
ROA-214.06%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-25.25M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-14808.49%
Net Debt1.67M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-1.10
Current Ratio0.26
Quick Ratio0.25
Book Value/Sh-3.74 USD
Cash/Share0.97 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 8, 2017
Splits
Last Split1:20
Split DateJan 18, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.85M
Float4.85M
Insiders0.00%
Institutions0.00%
Short Interest
Short Ratio0.1d
Short % Float3.30%
Short % Out.3.30%
Shares Short114.72K
Short (prev mo.)177.73K
Technical
SMA 500.0052 (+115.1%)
SMA 2000.0064 (+72.7%)
Beta29.95
S&P 52W Chg16.45%
Avg Vol (30d)290
Avg Vol (10d)0
Technical Indicators
RSI (14)82.7
MACD-0.0006
MACD Signal-0.0017
MACD Hist.+0.0010
BB Upper0.0056 USD
BB Middle0.0006 USD
BB Lower-0.0043 USD
BB Width1513.65%
ATR (14)0.0019 USD
Vol Ratio (20d)0.41x